Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, PCR, NGS), Disease (Hepatitis, HIV, HAI, TB, Flu, Syphilis), End User (Labs) - Global Forecast to 2030

icon1
USD 42.20 BN
MARKET SIZE, 2030
icon2
CAGR 9.7%
(2025-2030)
icon3
446
REPORT PAGES
icon4
541
MARKET TABLES

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The infectious disease diagnostics market is projected to grow from an estimated USD 26.58 billion in 2025 to USD 42.20 billion by 2030, reflecting a CAGR of 9.7% during the forecast period. Growth is driven by the increasing global burden of infectious diseases, heightened demand for timely and accurate diagnostic solutions, and continuous innovation in diagnostic technologies. Furthermore, government-led initiatives and funding programs are strengthening research & development efforts and enhancing healthcare infrastructure. These factors are collectively advancing diagnostic accessibility, driving technological progress, and supporting the sustained expansion of the infectious disease diagnostics market.

KEY TAKEAWAYS

  • BY PRODUCT & SERVICES
    Based on product and service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables, instruments, and software & services. The reagents, kits, and consumables segment is experiencing strong growth, driven by the rising number of infectious disease diagnostic tests, easy availability of a broad range of reagents, and the growing need for rapid, specific, and reliable detection of infections at an early stage.
  • BY TYPE OF TESTING
    Based on the type of testing, the infectious disease diagnostics market is segmented into laboratory testing and POC testing. Laboratory testing continues to play a critical role in the market, supported by the rising incidence of infectious diseases and the growing adoption of automation to improve efficiency.
  • BY SAMPLE TYPE
    Based on sample type, the infectious disease diagnostics market is segmented into blood, serum and plasma, urine, and other sample types. Blood, serum, and plasma are widely utilized in diagnostic testing as they provide a rich source of clinical information. These samples contain circulating DNA, RNA, proteins, and other biomarkers that offer critical insights into a wide range of infectious diseases.
  • BY TECHNOLOGY
    Based on technology, the infectious disease diagnostics market is broadly segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. Immunodiagnostics represents a key segment, driven by the widespread use of immunoassays in point of care infectious disease testing, ongoing development of innovative immunodiagnostic solutions.
  • BY DISEASE TYPE
    Based on disease type, the infectious disease diagnostics market is segmented into hepatitis, HIV, hospital-acquired infections, Chlamydia trachomatis, Neisseria gonorrhea, HPV, tuberculosis, influenza, syphilis, mosquito-borne diseases, and other infectious diseases. Hepatitis remains a major focus area, supported by advancements in diagnostic technologies such as serological assays and nucleic acid tests, which have significantly improved accuracy and efficiency.
  • BY CLINICAL APPLICATION
    Based on clinical application, the infectious disease diagnostics market has been segmented into diagnostic and screening. The diagnostic segment holds a significant position, supported by its critical role in confirming infections in symptomatic patients and guiding timely treatment decisions.
  • BY END USER
    Based on end user, the infectious disease diagnostics market has been segmented into hospitals & clinics, diagnostic laboratories, academic research institutes, and other end users. Diagnostic laboratories play a key role in the market, driven by the rising volume of infectious disease tests and ongoing enhancements in infrastructure that support efficient diagnosis and treatment.

The infectious disease diagnostics market is poised for robust growth over the coming years, driven by the rising prevalence of infectious diseases, increasing demand for timely and accurate diagnosis, and ongoing advancements in diagnostic technologies. Tools such as immunodiagnostics, molecular assays, and point-of-care testing platforms are being widely adopted to ensure rapid pathogen detection, guide treatment decisions, and improve patient outcomes. The growing burden of diseases such as hepatitis, HIV, tuberculosis, and hospital-acquired infections, coupled with heightened focus on early detection and preventive healthcare, is further boosting market adoption. Additionally, the expansion of diagnostic laboratories, increased healthcare spending, and integration of automated and high throughput testing solutions are enhancing accessibility, efficiency, and reliability in infectious disease diagnostics.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The infectious disease diagnostics market is experiencing significant shifts due to evolving healthcare needs and industry disruptions. Hospitals, diagnostic laboratories, and academic research institutes form the core customer base for diagnostic solution providers. Key trends such as the growing demand for rapid and accurate pathogen detection, increasing adoption of point of care and digital diagnostic platforms, emphasis on preventive healthcare, and evolving regulatory requirements are reshaping operational workflows and revenue models for these organizations. These developments influence their procurement of diagnostic instruments, reagents, and consumables, directly impacting the growth prospects and profitability of infectious disease diagnostics manufacturers.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising prevalence of infectious diseases
  • Rising focus on R&D and funding investments for infectious disease diagnostic products
RESTRAINTS
Impact
Level
  • Unfavorable reimbursements
OPPORTUNITIES
Impact
Level
  • High growth potential of emerging economies
CHALLENGES
Impact
Level
  • Stringent regulatory guidelines for IVD products
  • Operational barriers and shortage of skilled laboratory technicians

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising prevalence of infectious diseases

Infectious diseases such as tuberculosis, HIV/AIDS, hepatitis, sexually transmitted infections, and respiratory infections remain major global health concerns. Accurate and timely diagnosis is essential for effective treatment, disease management, and control. Early detection is critical for monitoring disease progression, limiting transmission, and improving patient outcomes. With the global burden of infectious diseases on the rise, demand for reliable and efficient diagnostic solutions continues to grow. Additionally, government health programs and public awareness initiatives are promoting wider adoption of diagnostic testing, supporting sustained long-term growth in the infectious disease diagnostics market.

Restraint: Unfavorable reimbursements

The growth of the infectious disease diagnostics market is constrained by inadequate and inconsistent reimbursement policies. Many advanced diagnostic tests, despite offering significant clinical benefits, receive limited coverage or low reimbursement from both public and private payers. This financial limitation discourages healthcare providers from adopting innovative diagnostic technologies, particularly in cost-sensitive healthcare settings, thereby restricting market expansion.

Opportunity: High growth potential of emerging economies.

Emerging markets are expected to provide substantial growth opportunities for the infectious disease diagnostics sector. This expansion is driven by high disease prevalence, growing patient populations, improving healthcare infrastructure, and rising disposable incomes. Factors such as the rise of medical tourism and government initiatives supporting healthcare modernization further bolster market potential. In particular, the Asia Pacific region offers a favorable regulatory environment with less stringent data requirements, making it an attractive market for the development and commercialization of diagnostic solutions.

Challenge: Operational barriers and shortage of skilled laboratory technicians

Clinical laboratories in major markets are continually evolving, presenting operational challenges for technicians in the efficient procurement, storage, and transportation of samples. These challenges are amplified with the adoption of advanced technologies such as Next-Generation Sequencing (NGS) and lab-on-a-chip PCR devices. Laboratories often need to reconfigure spaces to accommodate the specific requirements of infectious disease testing, ensuring accurate pathogen detection, preventing cross-contamination, and optimizing workflow efficiency. Consequently, the costs of maintaining and operating advanced diagnostic instruments, particularly those designed for single sample types have increased significantly.

Infectious Disease Diagnostics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Offers molecular diagnostic platforms such as COBAS PCR systems and Elecsys immunoassays for detecting infectious diseases including HIV, hepatitis, and influenza High accuracy and sensitivity, rapid turnaround time, high-throughput capability, integration with laboratory information systems, and improved clinical decision-making
Provides solutions such as Alinity m and ARCHITECT systems for molecular and immunodiagnostic testing of infectious diseases like HIV, and hepatitis B & C Reliable and fast results, scalable testing, reduced manual errors, automation-friendly, and supports timely patient management
Offers diagnostic platforms for molecular, immunoassay, and microbiology testing of infectious diseases Rapid and accurate pathogen detection, point of care testing options, workflow efficiency, and robust support for large-volume testing environments
Provides systems such as VIDAS and VITEK for immunoassay, molecular, and microbiology-based infectious disease diagnostics Enhanced diagnostic accuracy, early detection, streamlined laboratory workflow, reduced contamination risk, and comprehensive pathogen coverage
Provides PCR instruments, molecular assays, and sequencing solutions for infectious disease testing, including respiratory, blood-borne, and emerging pathogens High sensitivity and specificity, automation-ready, supports research and clinical labs, flexible testing platforms, and rapid reporting for timely intervention

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The infectious disease diagnostics market caters to a wide range of end users, including diagnostic laboratories, hospitals and clinics, academic research institutes, and other end users. This market is organized across technology segments such as immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification, DNA sequencing and next-generation sequencing, DNA microarray, and other technologies. The adoption of these technologies by end users is further supported by ongoing advancements in diagnostic products and a growing number of regulatory approvals, which together foster innovation and broaden clinical applications in infectious disease testing.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Infectious Disease Diagnostics Market, By Product & Services

Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables, instruments, and software & services. The demand for reagents, kits, and consumables is fueled by the growing volume of infectious disease tests, the need for rapid and reliable detection, and the wide availability of diagnostic products. Instruments and software adoption is driven by automation, high-throughput testing requirements, and the integration of digital platforms to streamline laboratory workflows and improve clinical decision-making.

Infectious Disease Diagnostics Market, By Type of Testing

Based on the type of testing, the infectious disease diagnostics market is segmented into laboratory testing and POC testing. Laboratory testing is driven by the need for accurate, high-throughput diagnostics and the adoption of molecular and immunoassay technologies. POC testing growth is supported by the increasing demand for rapid, bedside diagnostics, immediate clinical decision-making, and decentralized healthcare delivery.

Infectious Disease Diagnostics Market, By Sample Type

Based on sample type, the infectious disease diagnostics market is segmented into blood, serum and plasma, urine, and other sample types. Blood, serum, and plasma are widely used due to their rich biomarker content, enabling precise pathogen detection and disease monitoring. Urine and other sample types are increasingly adopted for non-invasive testing, improving patient compliance and facilitating early diagnosis in large populations.

Infectious Disease Diagnostics Market, By Technology

Based on technology, the infectious disease diagnostics market is broadly segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. Immunodiagnostics growth is driven by rapid, reliable assays suitable for high-throughput and POC testing. PCR and molecular methods benefit from high sensitivity and specificity, supporting early detection. NGS, microarrays, and advanced platforms are expanding diagnostic capabilities and enabling precision pathogen identification, contributing to broader clinical adoption.

Infectious Disease Diagnostics Market, By Disease Type

Based on disease type, the infectious disease diagnostics market is segmented into hepatitis, HIV, hospital-acquired infections, Chlamydia trachomatis, Neisseria gonorrhea, HPV, tuberculosis, influenza, syphilis, mosquito-borne diseases, and other infectious diseases. Hepatitis remains a major focus area, supported by advancements in diagnostic technologies such as serological assays and nucleic acid tests, which have significantly improved accuracy and efficiency.

Infectious Disease Diagnostics Market, By Clinical Application

Based on clinical application, the infectious disease diagnostics market has been segmented into diagnostic and screening. Diagnostic testing is fueled by the need to confirm infections, guide treatment decisions, and monitor disease progression. Screening demand is increasing due to preventive healthcare initiatives, population-wide surveillance, and early detection programs aimed at controlling infectious disease spread.

Infectious Disease Diagnostics Market, By End User

Based on end user, the infectious disease diagnostics market has been segmented into hospitals & clinics, diagnostic laboratories, academic research institutes, and other end users. Diagnostic laboratories benefit from high-throughput and automated platforms to handle large testing volumes. Academic and research institutes drive innovation through R&D, while other end users, such as public health agencies, rely on diagnostics for disease surveillance and outbreak management.

REGION

North America accounted for the largest share of the global infectious disease diagnostics market during the forecast period.

North America’s dominance in the global infectious disease diagnostics market is driven by several factors, including a high prevalence of infectious diseases such as HIV, hepatitis, and hospital-acquired infections, well-established healthcare infrastructure, and widespread adoption of advanced diagnostic technologies like PCR, NGS, and immunodiagnostics. Additionally, supportive government initiatives, extensive public health programs, and substantial healthcare spending facilitate early detection, accurate diagnosis, and efficient disease management, reinforcing the region’s leading position in the market.

Infectious Disease Diagnostics Market: COMPANY EVALUATION MATRIX

F. Hoffmann-La Roche Ltd. (Switzerland) is a leading player in the infectious disease diagnostics market. The company’s strong position is supported by an extensive distribution network across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. By leveraging a combination of direct and indirect distribution channels, Roche effectively manages regional demand fluctuations. The company also enhances its market presence and global reach through strategic partnerships and acquisitions.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size Value in 2024 USD 24.96 Billion
Revenue Forecast in 2030 USD 42.20 Billion
Growth Rate CAGR of 9.7% from 2025-2030
Actual Data 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Million), Volume (Million)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product & Service (Reagents, Kits, and Consumables, Instruments, Software & Services), Type of Testing (Laboratory Testing, PoC Testing), Sample Type (Blood, Serum, and Plasma, Urine, Other Sample Types), Disease Type (Hepatitis, HIV, HAIs, Mosquito-borne Diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhoeae, Tuberculosis, Influenza, Syphilis, Other Infectious Diseases), Technology (Immunodiagnostics, Polymerase Chain Reaction (PCR), Clinical Microbiology, Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-generation Sequencing (NGS), DNA Microarray, Other Technologies), End User (Diagnostic Laboratories, Hospitals & Clinics, Academic Research Institutes, Other End Users)
Regional Scope North America, Europe, Asia Pacific, Latin America and the Middle East & Africa

WHAT IS IN IT FOR YOU: Infectious Disease Diagnostics Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS

RECENT DEVELOPMENTS

  • June 2025 : Becton, Dickinson and Company (US) received US FDA 510(k) clearance for the BD Phoenix M50 and BDXpert System on the BD Synapsys Informatics Solution, leveraging rapid identification (ID) and antimicrobial susceptibility testing (AST) algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate & reliable diagnoses related to antimicrobial resistance (AMR).
  • March 2025 : bioMérieux (France) announced US FDA 510(k) clearance for VITEK COMPACT PRO. This system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will help clinical laboratories diagnose infectious diseases and combat antimicrobial resistance.
  • May 2025 : Revvity, Inc. (US) launched the IDS i20 analytical platform from EUROIMMUN, a fully automated, random-access system for chemiluminescence immunoassays (ChLIA). The CE-marked and FDA-listed IDS i20 enables high-throughput infectious disease testing alongside other specialty assays.
  • September 2024 : F. Hoffmann-La Roche Ltd. (Switzerland) launched its cobas Respiratory flex test, the first to use Roche’s novel and proprietary TAGS (Temperature-Activated Generation of Signal) technology. TAGS technology uses multiplex polymerase chain reaction (PCR) testing, color, temperature, and data processing, to identify as many as 15 pathogens in a single PCR test.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
39
2
RESEARCH METHODOLOGY
 
 
 
44
3
EXECUTIVE SUMMARY
 
 
 
58
4
PREMIUM INSIGHTS
 
 
 
64
5
MARKET OVERVIEW
Emerging markets and tech innovations drive infectious disease diagnostics' decentralized growth.
 
 
 
69
 
5.1
INTRODUCTION
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
5.2.1.1
RISING PREVALENCE OF INFECTIOUS DISEASES
 
 
 
 
5.2.1.2
RISING FOCUS ON R&D AND FUNDING INVESTMENTS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
 
 
 
 
5.2.1.3
ADOPTION OF INNOVATIVE & ADVANCED TECHNOLOGIES FOR INFECTIOUS DISEASE DIAGNOSIS
 
 
 
 
5.2.1.4
GRADUAL SHIFT FROM CENTRALIZED LABORATORIES TO DECENTRALIZED POC TESTING CENTERS
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
5.2.2.1
UNFAVORABLE REIMBURSEMENTS
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
5.2.3.1
HIGH GROWTH POTENTIAL OF EMERGING ECONOMIES
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
5.2.4.1
STRINGENT REGULATORY GUIDELINES FOR IVD PRODUCTS
 
 
 
 
5.2.4.2
OPERATIONAL BARRIERS AND SHORTAGE OF SKILLED LABORATORY TECHNICIANS
 
 
5.3
PRICING ANALYSIS
 
 
 
 
 
 
5.3.1
INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023−2025
 
 
 
 
5.3.2
INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023−2025
 
 
 
 
5.3.3
INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023−2025
 
 
 
5.4
PATENT ANALYSIS
 
 
 
 
 
 
5.4.1
LIST OF MAJOR PATENTS
 
 
 
5.5
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.6
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
5.7
TRADE ANALYSIS
 
 
 
 
 
 
5.7.1
TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
 
 
 
 
5.7.2
IMPORT DATA (HS CODE 3822)
 
 
 
 
5.7.3
EXPORT DATA (HS CODE 3822)
 
 
 
5.8
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
5.8.1
INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
 
 
 
5.9
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
5.9.1
THREAT OF NEW ENTRANTS
 
 
 
 
5.9.2
THREAT OF SUBSTITUTES
 
 
 
 
5.9.3
BARGAINING POWER OF BUYERS
 
 
 
 
5.9.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
5.9.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
5.10
REGULATORY LANDSCAPE
 
 
 
 
 
5.10.1
REGULATORY FRAMEWORK
 
 
 
 
 
5.10.1.1
NORTH AMERICA
 
 
 
 
5.10.1.2
EUROPE
 
 
 
 
5.10.1.3
ASIA PACIFIC
 
 
 
 
5.10.1.4
LATIN AMERICA
 
 
 
 
5.10.1.5
MIDDLE EAST
 
 
 
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
5.11
TECHNOLOGY ANALYSIS
 
 
 
 
 
5.11.1
KEY TECHNOLOGIES
 
 
 
 
 
5.11.1.1
IMMUNODIAGNOSTICS
 
 
 
5.11.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
5.11.2.1
POLYMERASE CHAIN REACTION (PCR)
 
 
 
5.11.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
5.11.3.1
NEXT-GENERATION SEQUENCING (NGS)
 
 
5.12
KEY CONFERENCES & EVENTS, 2025–2026
 
 
 
 
5.13
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
5.14
KEY STAKEHOLDERS & BUYING CRITERIA
 
 
 
 
 
 
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
5.14.2
BUYING CRITERIA
 
 
 
5.15
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
5.16
CASE STUDY ANALYSIS
 
 
 
 
 
5.16.1
CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
 
 
 
 
5.16.2
CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS
 
 
 
 
5.16.3
CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS
 
 
 
5.17
IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
 
 
 
 
 
 
5.17.1
INTRODUCTION
 
 
 
 
5.17.2
MARKET POTENTIAL OF AI
 
 
 
 
5.17.3
AI-USE CASES
 
 
 
 
5.17.4
IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
 
 
 
 
5.17.5
FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
 
 
 
5.18
TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
 
 
 
 
 
5.18.1
INTRODUCTION
 
 
 
 
5.18.2
KEY TARIFF RATES
 
 
 
 
5.18.3
PRICE IMPACT ANALYSIS
 
 
 
 
5.18.4
KEY IMPACT ON COUNTRY/REGION
 
 
 
 
 
5.18.4.1
NORTH AMERICA
 
 
 
 
5.18.4.2
EUROPE
 
 
 
 
5.18.4.3
ASIA PACIFIC
 
 
 
5.18.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
5.18.5.1
DIAGNOSTIC LABORATORIES
 
 
 
 
5.18.5.2
HOSPITALS & CLINICS
 
 
 
 
5.18.5.3
ACADEMIC RESEARCH INSTITUTES
 
6
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
 
 
 
108
 
6.1
INTRODUCTION
 
 
 
 
6.2
REAGENTS, KITS, AND CONSUMABLES
 
 
 
 
 
6.2.1
RECURRENT PURCHASE TO PROPEL MARKET
 
 
 
6.3
INSTRUMENTS
 
 
 
 
 
6.3.1
RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET
 
 
 
6.4
SOFTWARE & SERVICES
 
 
 
 
 
6.4.1
INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH
 
 
7
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
 
 
 
122
 
7.1
INTRODUCTION
 
 
 
 
7.2
LABORATORY TESTING
 
 
 
 
 
7.2.1
HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE
 
 
 
7.3
POC TESTING
 
 
 
 
 
7.3.1
RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET
 
 
8
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
 
 
 
130
 
8.1
INTRODUCTION
 
 
 
 
8.2
BLOOD, SERUM, AND PLASMA
 
 
 
 
 
8.2.1
HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET
 
 
 
8.3
URINE
 
 
 
 
 
8.3.1
NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND
 
 
 
8.4
OTHER SAMPLE TYPES
 
 
 
9
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 96 Data Tables
 
 
 
140
 
9.1
INTRODUCTION
 
 
 
 
9.2
HEPATITIS
 
 
 
 
 
9.2.1
HEPATITIS B
 
 
 
 
 
9.2.1.1
HIGHLY CONTAGIOUS INFECTION AND REQUIREMENT FOR REGULAR MONITORING TO FUEL MARKET
 
 
 
9.2.2
HEPATITIS C
 
 
 
 
 
9.2.2.1
RISING INCIDENCE OF CHRONIC HCV AND SUPPORTIVE GOVERNMENT INITIATIVES TO DRIVE MARKET
 
 
 
9.2.3
OTHER HEPATITIS DISEASES
 
 
 
9.3
HIV
 
 
 
 
 
9.3.1
INCREASING PREVALENCE OF AIDS TO BOOST DEMAND
 
 
 
9.4
HOSPITAL-ACQUIRED INFECTIONS
 
 
 
 
 
9.4.1
RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET
 
 
 
9.5
MOSQUITO-BORNE DISEASES
 
 
 
 
 
9.5.1
RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET
 
 
 
9.6
HPV
 
 
 
 
 
9.6.1
RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND
 
 
 
9.7
CHLAMYDIA TRACHOMATIS
 
 
 
 
 
9.7.1
INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE
 
 
 
9.8
NEISSERIA GONORRHEA
 
 
 
 
 
9.8.1
RISING INCIDENCE OF GONORRHEA TO FUEL MARKET
 
 
 
9.9
TUBERCULOSIS
 
 
 
 
 
9.9.1
INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET
 
 
 
9.10
INFLUENZA
 
 
 
 
 
9.10.1
INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET
 
 
 
9.11
SYPHILIS
 
 
 
 
 
9.11.1
IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE
 
 
 
9.12
OTHER INFECTIOUS DISEASES
 
 
 
10
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 49 Data Tables
 
 
 
184
 
10.1
INTRODUCTION
 
 
 
 
10.2
IMMUNODIAGNOSTICS
 
 
 
 
 
10.2.1
RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
 
 
 
10.3
CLINICAL MICROBIOLOGY
 
 
 
 
 
10.3.1
RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND
 
 
 
10.4
POLYMERASE CHAIN REACTION
 
 
 
 
 
10.4.1
CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE
 
 
 
10.5
ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
 
 
 
 
 
10.5.1
ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE
 
 
 
10.6
DNA SEQUENCING & NEXT-GENERATION SEQUENCING
 
 
 
 
 
10.6.1
ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET
 
 
 
10.7
DNA MICROARRAY
 
 
 
 
 
10.7.1
HIGH INSTRUMENT COSTS TO LIMIT MARKET
 
 
 
10.8
OTHER TECHNOLOGIES
 
 
 
11
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
 
 
 
206
 
11.1
INTRODUCTION
 
 
 
 
11.2
DIAGNOSTICS
 
 
 
 
 
11.2.1
INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET
 
 
 
11.3
SCREENING
 
 
 
 
 
11.3.1
GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET
 
 
12
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 25 Data Tables
 
 
 
214
 
12.1
INTRODUCTION
 
 
 
 
12.2
DIAGNOSTIC LABORATORIES
 
 
 
 
 
12.2.1
ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET
 
 
 
12.3
HOSPITALS & CLINICS
 
 
 
 
 
12.3.1
IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET
 
 
 
12.4
ACADEMIC RESEARCH INSTITUTES
 
 
 
 
 
12.4.1
INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET
 
 
 
12.5
OTHER END USERS
 
 
 
13
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 196 Data Tables.
 
 
 
227
 
13.1
INTRODUCTION
 
 
 
 
13.2
NORTH AMERICA
 
 
 
 
 
13.2.1
NORTH AMERICA: MACROECONOMIC OUTLOOK
 
 
 
 
13.2.2
US
 
 
 
 
 
13.2.2.1
HIGH HEALTHCARE EXPENDITURE TO DRIVE MARKET
 
 
 
13.2.3
CANADA
 
 
 
 
 
13.2.3.1
SUPPORTIVE GOVERNMENT INITIATIVES FOR INFECTIOUS DISEASE PREVENTION TO FUEL MARKET
 
 
13.3
EUROPE
 
 
 
 
 
13.3.1
EUROPE: MACROECONOMIC OUTLOOK
 
 
 
 
13.3.2
GERMANY
 
 
 
 
 
13.3.2.1
HIGH ADOPTION OF ADVANCED TECHNOLOGIES TO PROPEL MARKET
 
 
 
13.3.3
UK
 
 
 
 
 
13.3.3.1
INCREASING NUMBER OF DIAGNOSTIC CENTERS TO FUEL UPTAKE
 
 
 
13.3.4
FRANCE
 
 
 
 
 
13.3.4.1
RISING EXPENDITURE ON LIFE SCIENCES R&D TO DRIVE MARKET
 
 
 
13.3.5
ITALY
 
 
 
 
 
13.3.5.1
RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND
 
 
 
13.3.6
SPAIN
 
 
 
 
 
13.3.6.1
HIGH PREVALENCE OF HIV AND CONSOLIDATION OF DIAGNOSTIC LABORATORIES TO DRIVE MARKET
 
 
 
13.3.7
REST OF EUROPE
 
 
 
13.4
ASIA PACIFIC
 
 
 
 
 
13.4.1
ASIA PACIFIC: MACROECONOMIC OUTLOOK
 
 
 
 
13.4.2
CHINA
 
 
 
 
 
13.4.2.1
INCREASING BURDEN OF HEPATITIS B VIRUS CASES AND GROWING GOVERNMENT FOCUS ON HEALTH SURVEILLANCE TO DRIVE MARKET
 
 
 
13.4.3
JAPAN
 
 
 
 
 
13.4.3.1
PRESENCE OF ESTABLISHED HEALTHCARE SYSTEM AND UNIVERSAL REIMBURSEMENT POLICIES TO FUEL UPTAKE
 
 
 
13.4.4
INDIA
 
 
 
 
 
13.4.4.1
HIGH PREVALENCE OF TB & HIV TO PROPEL MARKET
 
 
 
13.4.5
REST OF ASIA PACIFIC
 
 
 
13.5
LATIN AMERICA
 
 
 
 
 
13.5.1
LATIN AMERICA: MACROECONOMIC OUTLOOK
 
 
 
 
13.5.2
BRAZIL
 
 
 
 
 
13.5.2.1
RISING FOCUS ON INITIATING PUBLIC-PRIVATE INVESTMENTS FOR HEALTHCARE IMPROVEMENT TO FUEL UPTAKE
 
 
 
13.5.3
MEXICO
 
 
 
 
 
13.5.3.1
IMPROVING ACCESSIBILITY & AFFORDABILITY OF HEALTHCARE SERVICES TO SUPPORT MARKET GROWTH
 
 
 
13.5.4
REST OF LATIN AMERICA
 
 
 
13.6
MIDDLE EAST & AFRICA
 
 
 
 
 
13.6.1
MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
 
 
 
 
13.6.2
KINGDOM OF SAUDI ARABIA (KSA)
 
 
 
 
 
13.6.2.1
INTEGRATION OF DIGITAL HEALTH SYSTEMS AND IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO FUEL MARKET
 
 
 
13.6.3
UNITED ARAB EMIRATES (UAE)
 
 
 
 
 
13.6.3.1
RISING REQUIREMENT OF HIGH-QUALITY HEALTHCARE SERVICES TO SUPPORT MARKET GROWTH
 
 
 
13.6.4
REST OF MIDDLE EAST & AFRICA
 
 
14
COMPETITIVE LANDSCAPE
Discover key players' strategies and market dominance in infectious disease diagnostics.
 
 
 
332
 
14.1
INTRODUCTION
 
 
 
 
14.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
14.2.1
OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
 
 
 
14.3
REVENUE SHARE ANALYSIS, 2022−2024
 
 
 
 
14.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
14.5.1
STARS
 
 
 
 
14.5.2
EMERGING LEADERS
 
 
 
 
14.5.3
PERVASIVE PLAYERS
 
 
 
 
14.5.4
PARTICIPANTS
 
 
 
 
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
14.5.5.1
COMPANY FOOTPRINT
 
 
 
 
14.5.5.2
REGION FOOTPRINT
 
 
 
 
14.5.5.3
PRODUCT & SERVICE FOOTPRINT
 
 
 
 
14.5.5.4
TYPE OF TESTING FOOTPRINT
 
 
 
 
14.5.5.5
SAMPLE TYPE FOOTPRINT
 
 
14.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
14.6.1
PROGRESSIVE COMPANIES
 
 
 
 
14.6.2
RESPONSIVE COMPANIES
 
 
 
 
14.6.3
DYNAMIC COMPANIES
 
 
 
 
14.6.4
STARTING BLOCKS
 
 
 
 
14.6.5
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
14.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
14.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
 
 
 
 
14.6.5.3
COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
 
 
14.7
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
14.7.1
FINANCIAL METRICS
 
 
 
 
14.7.2
COMPANY VALUATION
 
 
 
14.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
14.8.1
BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
14.9
COMPETITIVE SCENARIO
 
 
 
 
 
14.9.1
PRODUCT/SERVICES LAUNCHES & APPROVALS
 
 
 
 
14.9.2
DEALS
 
 
 
 
14.9.3
EXPANSIONS
 
 
15
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
349
 
15.1
KEY PLAYERS
 
 
 
 
 
15.1.1
F. HOFFMANN-LA ROCHE LTD.
 
 
 
 
 
15.1.1.1
BUSINESS OVERVIEW
 
 
 
 
15.1.1.2
PRODUCTS/SERVICES OFFERED
 
 
 
 
15.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.1.4
MNM VIEW
 
 
 
15.1.2
ABBOTT
 
 
 
 
15.1.3
DANAHER CORPORATION
 
 
 
 
15.1.4
BIOMÉRIEUX
 
 
 
 
15.1.5
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
15.1.6
SIEMENS HEALTHINEERS AG
 
 
 
 
15.1.7
HOLOGIC, INC.
 
 
 
 
15.1.8
BECTON, DICKINSON AND COMPANY (BD)
 
 
 
 
15.1.9
REVVITY, INC.
 
 
 
 
15.1.10
QIAGEN N.V.
 
 
 
 
15.1.11
SEEGENE INC.
 
 
 
15.2
OTHER PLAYERS
 
 
 
 
 
15.2.1
QUIDELORTHO CORPORATION
 
 
 
 
15.2.2
GRIFOLS, S.A.
 
 
 
 
15.2.3
DIASORIN S.P.A
 
 
 
 
15.2.4
BIO-RAD LABORATORIES, INC.
 
 
 
 
15.2.5
SYSMEX CORPORATION
 
 
 
 
15.2.6
ORASURE TECHNOLOGIES, INC.
 
 
 
 
15.2.7
CO-DIAGNOSTICS, INC.
 
 
 
 
15.2.8
SD BIOSENSOR, INC.
 
 
 
 
15.2.9
BIOSYNEX SA
 
 
 
 
15.2.10
TRINITY BIOTECH
 
 
 
 
15.2.11
BRUKER (ELITECHGROUP)
 
 
 
 
15.2.12
GENETIC SIGNATURES
 
 
 
 
15.2.13
EPITOPE DIAGNOSTICS, INC.
 
 
 
 
15.2.14
TRIVITRON HEALTHCARE
 
 
 
 
15.2.15
MERIL LIFE SCIENCES PVT. LTD.
 
 
 
 
15.2.16
INBIOS INTERNATIONAL, INC.
 
 
 
 
15.2.17
UNIOGEN OY
 
 
 
 
15.2.18
VELA DIAGNOSTICS
 
 
 
 
15.2.19
MOLBIO DIAGNOSTICS LIMITED
 
 
16
APPENDIX
 
 
 
438
 
16.1
DISCUSSION GUIDE
 
 
 
 
16.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
16.3
CUSTOMIZATION OPTIONS
 
 
 
 
16.4
RELATED REPORTS
 
 
 
 
16.5
AUTHOR DETAILS
 
 
 
LIST OF TABLES
 
 
 
 
 
TABLE 1
INFECTIOUS DISEASE DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
 
 
 
 
TABLE 2
INFECTIOUS DISEASE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
 
 
 
 
TABLE 3
INFECTIOUS DISEASE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
 
 
 
 
TABLE 4
REGIONAL HIV DATA, 2024
 
 
 
 
TABLE 5
INDICATIVE SELLING PRICING TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2023–2025
 
 
 
 
TABLE 6
INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER, 2023–2025
 
 
 
 
TABLE 7
INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025
 
 
 
 
TABLE 8
INFECTIOUS DISEASE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS
 
 
 
 
TABLE 9
IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
 
 
 
 
TABLE 10
EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION)
 
 
 
 
TABLE 11
INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
 
 
 
 
TABLE 12
INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
TABLE 13
CLASSIFICATION OF IVD DEVICES IN EUROPE
 
 
 
 
TABLE 14
TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
 
 
 
 
TABLE 17
ASIA PACIFIC: LIST OF KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 20
INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
 
 
 
 
TABLE 21
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
 
 
 
 
TABLE 22
KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY RANK
 
 
 
 
TABLE 23
IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
 
 
 
 
TABLE 24
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
TABLE 25
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)T
 
 
 
 
TABLE 26
KEY REAGENTS, KITS, AND CONSUMABLES CURRENTLY AVAILABLE
 
 
 
 
TABLE 27
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 28
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 29
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 30
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 31
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 32
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 33
KEY INSTRUMENTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 34
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 35
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 36
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 37
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 38
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 39
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 40
KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE
 
 
 
 
TABLE 41
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 42
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 43
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 44
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 45
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 46
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 47
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 48
KEY LABORATORY TEST TYPES CURRENTLY AVAILABLE
 
 
 
 
TABLE 49
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 50
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 51
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 52
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 53
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 54
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 55
KEY POC TESTING TYPES CURRENTLY AVAILABLE
 
 
 
 
TABLE 56
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 57
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 58
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 59
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 60
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 61
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 62
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 63
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 64
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 65
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 66
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 67
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 68
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 69
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 70
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 71
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 72
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 73
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 74
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 75
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 76
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 77
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 78
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 79
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 80
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 81
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 82
KEY HEPATITIS TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 83
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 84
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 85
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 86
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 87
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 88
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 89
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 90
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 91
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 92
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 93
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 94
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 95
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 96
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 97
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 98
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 99
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 100
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 101
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 102
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 103
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 104
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 105
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 106
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 107
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 108
KEY HIV TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 109
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 110
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 111
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 112
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 113
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 114
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 115
KEY HAI TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 116
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 117
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 118
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 119
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 120
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 121
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 122
KEY DENGUE-TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 123
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 124
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 125
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 126
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 127
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 128
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 129
KEY HPV TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 130
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 131
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 132
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 133
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 134
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 135
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 136
KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 137
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 138
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 139
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 140
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 141
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 142
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 143
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 144
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 145
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 146
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 147
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 148
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 149
KEY TUBERCULOSIS TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 150
GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (IN MILLIONS)
 
 
 
 
TABLE 151
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 152
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 153
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 154
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 155
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 156
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 157
KEY INFLUENZA TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 158
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 159
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 160
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 161
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 162
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 163
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 164
KEY SYPHILIS TESTING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 165
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 166
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 167
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 168
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 169
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 170
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 171
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 172
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 173
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 174
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 175
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 176
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 177
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 178
KEY IMMUNODIAGNOSTICS-BASED PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 179
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 180
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 181
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 182
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 183
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 184
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 185
KEY CLINICAL MICROBIOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 186
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 187
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 188
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 189
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 190
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 191
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 192
KEY POLYMERASE CHAIN REACTION-BASED PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 193
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 194
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 195
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 196
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 197
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 198
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 199
KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 200
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 201
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 202
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 203
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 204
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 205
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 206
KEY DNA SEQUENCING & NEXT-GENERATION SEQUENCING-BASED PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 207
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 208
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 209
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 210
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 211
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 212
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 213
KEY DNA MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 214
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 215
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 216
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 217
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 218
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 219
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 220
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 221
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 222
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 223
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 224
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 225
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 226
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 227
KEY DIAGNOSTICS PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 228
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 229
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 230
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 231
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 232
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 233
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 234
KEY SCREENING PRODUCTS CURRENTLY AVAILABLE
 
 
 
 
TABLE 235
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 236
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 237
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 238
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 239
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 240
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 241
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 242
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 243
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 244
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 245
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 246
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 247
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 248
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 249
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 250
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 251
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 252
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 253
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 254
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 255
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 256
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 257
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 258
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 259
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 260
INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 261
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 262
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 263
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 264
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 265
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 266
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 267
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 268
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 269
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 270
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 271
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 272
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 273
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 274
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 275
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 276
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 277
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 278
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 279
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 280
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 281
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 282
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 283
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 284
US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 285
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 286
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 287
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 288
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 289
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 290
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 291
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 292
CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 293
EUROPE: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 294
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 295
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 296
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 297
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 298
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 299
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 300
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 301
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 302
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 303
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 304
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 305
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 306
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 307
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 308
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 309
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 310
GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 311
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 312
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 313
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 314
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 315
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 316
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 317
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 318
UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 319
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 320
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 321
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 322
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 323
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 324
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 325
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 326
FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 327
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 328
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 329
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 330
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 331
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 332
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 333
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 334
ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 335
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 336
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 337
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 338
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 339
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 340
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 341
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 342
SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 343
GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)
 
 
 
 
TABLE 344
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 345
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 346
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 347
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 348
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 349
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 350
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 351
REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 352
ASIA PACIFIC: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 353
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 354
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 355
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 356
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 357
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 358
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 359
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 360
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 361
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 362
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 363
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 364
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 365
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 366
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 367
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 368
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 369
CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 370
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 371
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 372
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 373
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 374
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 375
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 376
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 377
JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 378
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 379
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 380
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 381
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 382
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 383
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 384
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 385
INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 386
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 387
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 388
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 389
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 390
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 391
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 392
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 393
REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 394
LATIN AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 395
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 396
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 397
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 398
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 399
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 400
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 401
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 402
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 403
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 404
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 405
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 406
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 407
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 408
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 409
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 410
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 411
BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 412
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 413
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 414
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 415
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 416
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 417
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 418
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 419
MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 420
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 421
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 422
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 423
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 424
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 425
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 426
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 427
REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 428
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 429
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 430
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 431
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 432
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 433
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 434
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 435
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 436
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 437
MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 438
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 439
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 440
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 441
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 442
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 443
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 444
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 445
KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 446
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 447
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 448
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 449
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 450
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 451
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 452
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 453
UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 454
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 455
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 456
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 457
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 458
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 459
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 460
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 461
REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 462
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET, JANUARY 2021−JUNE 2025
 
 
 
 
TABLE 463
INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
 
 
 
 
TABLE 464
INFECTIOUS DISEASE DIAGNOSTICS MARKET: REGION FOOTPRINT
 
 
 
 
TABLE 465
INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
 
 
 
 
TABLE 466
INFECTIOUS DISEASE DIAGNOSTICS MARKET: TYPE OF TESTING FOOTPRINT
 
 
 
 
TABLE 467
INFECTIOUS DISEASE DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT
 
 
 
 
TABLE 468
INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
TABLE 469
INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
 
 
 
 
TABLE 470
INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
 
 
 
 
TABLE 471
INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 472
INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 473
INFECTIOUS DISEASE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021– JUNE 2025
 
 
 
 
TABLE 474
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 475
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 476
F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 477
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−JUNE 2025
 
 
 
 
TABLE 478
F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 479
ABBOTT: COMPANY OVERVIEW
 
 
 
 
TABLE 480
ABBOTT: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 481
ABBOTT: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 482
ABBOTT: DEALS, JANUARY 2021−JUNE 2025
 
 
 
 
TABLE 483
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 484
DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 485
DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 486
DANAHER CORPORATION: DEALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 487
DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−JUNE 2025
 
 
 
 
TABLE 488
BIOMÉRIEUX: COMPANY OVERVIEW
 
 
 
 
TABLE 489
BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 490
BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 491
BIOMÉRIEUX: DEALS, JANUARY 2021– JUNE 2025
 
 
 
 
TABLE 492
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 493
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 494
THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 495
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 496
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
 
 
 
 
TABLE 497
SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 498
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 499
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021−JUNE 2025
 
 
 
 
TABLE 500
SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021−JUNE 2025
 
 
 
 
TABLE 501
HOLOGIC, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 502
HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 503
HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 504
HOLOGIC, INC.: DEALS, JANUARY 2021– JUNE 2025
 
 
 
 
TABLE 505
BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
 
 
 
 
TABLE 506
BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 507
BECTON, DICKINSON AND COMPANY: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 508
BD: DEALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 509
BD: EXPANSIONS, JANUARY 2021– JUNE 2025
 
 
 
 
TABLE 510
REVVITY, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 511
REVVITY, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 512
REVVITY INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 513
QIAGEN N.V.: COMPANY OVERVIEW
 
 
 
 
TABLE 514
QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 515
QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 516
QIAGEN N.V.: DEALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 517
QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 518
SEEGENE INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 519
SEEGENE INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 520
SEEGENE INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025
 
 
 
 
TABLE 521
SEEGENE INC.: DEALS, JANUARY 2021– JUNE 2025
 
 
 
 
TABLE 522
SEEGENE INC.: EXPANSIONS, JANUARY 2021– JUNE 2025
 
 
 
 
TABLE 523
QUIDELORTHO CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 524
GRIFOLS, S.A.: COMPANY OVERVIEW
 
 
 
 
TABLE 525
DIASORIN S.P.A.: COMPANY OVERVIEW
 
 
 
 
TABLE 526
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 527
SYSMEX CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 528
ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 529
CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 530
SD BIOSENSOR, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 531
BIOSYNEX SA: COMPANY OVERVIEW
 
 
 
 
TABLE 532
TRINITY BIOTECH: COMPANY OVERVIEW
 
 
 
 
TABLE 533
BRUKER (ELITECHGROUP): COMPANY OVERVIEW
 
 
 
 
TABLE 534
GENETIC SIGNATURES: COMPANY OVERVIEW
 
 
 
 
TABLE 535
EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 536
TRIVITRON HEALTHCARE: COMPANY OVERVIEW
 
 
 
 
TABLE 537
MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 538
INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 539
UNIOGEN OY: COMPANY OVERVIEW
 
 
 
 
TABLE 540
VELA DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
TABLE 541
MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
FIGURE 1
INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
 
 
 
 
FIGURE 2
INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
 
 
 
 
FIGURE 3
PRIMARY SOURCES
 
 
 
 
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
FIGURE 6
BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
 
 
 
 
FIGURE 7
CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS T
 
 
 
 
FIGURE 8
INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
 
 
 
 
FIGURE 9
DATA TRIANGULATION METHODOLOGY
 
 
 
 
FIGURE 10
INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
 
 
 
 
FIGURE 11
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 12
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 13
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 14
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 15
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 16
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 17
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 18
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 19
RISING FOCUS ON R&D FOR INFECTIOUS DISEASE DIAGNOSTICS TO PROPEL MARKET
 
 
 
 
FIGURE 20
REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 21
LABORATORY TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 22
BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 23
HEPATITIS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 24
IMMUNODIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 25
DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 26
DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 27
ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
 
 
 
FIGURE 28
INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
FIGURE 29
PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2015–DECEMBER 2024)
 
 
 
 
FIGURE 30
VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES
 
 
 
 
FIGURE 31
INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
FIGURE 32
INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
FIGURE 33
INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
FIGURE 34
INFECTIOUS DISEASE DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
FIGURE 35
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
 
 
 
 
FIGURE 36
KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
 
 
 
 
FIGURE 37
NUMBER OF DEALS & FUNDING ACTIVITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
 
 
 
 
FIGURE 38
MARKET POTENTIAL OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
 
 
 
 
FIGURE 39
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
FIGURE 40
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
FIGURE 41
REVENUE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2022–2024)
 
 
 
 
FIGURE 42
MARKET SHARE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2024)
 
 
 
 
FIGURE 43
INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
FIGURE 44
INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
 
 
 
 
FIGURE 45
INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
FIGURE 46
EV/EBITDA OF KEY VENDORS
 
 
 
 
FIGURE 47
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
FIGURE 48
INFECTIOUS DISEASE DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS
 
 
 
 
FIGURE 49
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 50
ABBOTT: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 51
DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 52
BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 53
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 54
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 55
HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 56
BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 57
REVVITY, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 58
QIAGEN N.V.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 59
SEEGENE INC.: COMPANY SNAPSHOT (2024)
 
 
 
 

Methodology

The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. The objectives include tracking company developments such as acquisitions, product/service launches & approvals, expansions, agreements, and partnerships of the leading players. These parameters were evaluated on various parameters within the broad business & product strategy categories. Top-down and bottom-up approaches were used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

The four steps involved in estimating the market size are:

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify & collect information for this study.

Primary Research

In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative & quantitative information for this report. Primary sources included experts from the core & related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain & verify critical qualitative & quantitative information and assess prospects.

The following is a breakdown of the primary respondents:

Infectious Disease Diagnostics Market

Note 1: Others include sales, marketing, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
Abbott (US) Sales Manager
Becton, Dickinson and Company (US) Product Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate & validate the infectious disease diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the infectious disease diagnostics market have been determined through primary & secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Infectious Disease Diagnostics Market

Data Triangulation

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Infectious disease diagnostics can be defined as various techniques and products (including kits, assays, tests, reagents, and analyzers) used by healthcare professionals to detect and diagnose disease-causing pathogens in human samples such as serum, blood, urine, throat swabs, and stool, among others.

Stakeholders

  • Manufacturers & distributors of infectious disease diagnostics
  • IVD companies
  • Hospitals & clinics
  • Academic research institutes
  • Diagnostic laboratories
  • Blood banks
  • Home health agencies
  • Market research & consulting firms
  • Government associations
  • Venture capitalists & investors

Report Objectives

  • To define, describe, segment, and forecast the global infectious disease diagnostics market by product & service, type of testing, sample type, disease type, technology, clinical application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall infectious disease diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the infectious disease diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings

 

Key Questions Addressed by the Report

What are the recent trends affecting the infectious disease diagnostics market?

The market is influenced by the rising incidence of infectious diseases, growing public awareness about early diagnosis, and the increasing size of the geriatric population. These trends are driving demand for timely and accurate diagnostic solutions.

What are the leading technologies in the infectious disease diagnostics market?

Leading technologies include immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing and next-generation sequencing, and DNA microarray technologies.

Who are the key players in the infectious disease diagnostics market?

Key players include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), and Bio-Rad Laboratories, Inc. (US).

What are the leading sample types in the infectious disease diagnostics market?

The market is segmented by sample type into blood, serum, and plasma; urine; and other types. The blood, serum, and plasma segment dominates due to its ability to carry a wide range of biomarkers, including DNA, RNA, proteins, and pathogens.

Which region is lucrative for the infectious disease diagnostics market?

The Asia Pacific region, especially countries like China and India, offers significant growth potential due to expanding healthcare infrastructure and rising demand for diagnostic products and services.

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Infectious Disease Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Infectious Disease Diagnostics Market

Mason

Jun, 2022

What are the challenges faced by the key players of the Infectious Disease Diagnostics Market?.

Reuben

Jun, 2022

Which of the segments of Infectious Disease Diagnostics Market is expected to hold the major share?.

Albie

Jun, 2022

How the technological innovations are boosting the global growth of Infectious Disease Diagnostics Market?.

DMCA.com Protection Status